Shares of Exagen Inc. (NYSE:XGN) have been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.
Brokerages have set a one year consensus price objective of $17.50 for the company and are predicting that the company will post ($4.22) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Exagen an industry rank of 104 out of 255 based on the ratings given to related companies.
Several equities research analysts recently commented on XGN shares. William Blair started coverage on Exagen in a research report on Monday, October 14th. They set an “outperform” rating on the stock. Cantor Fitzgerald started coverage on Exagen in a research report on Monday, October 14th. They set an “overweight” rating and a $18.00 target price on the stock. Finally, Cowen started coverage on Exagen in a research report on Monday, October 14th. They set an “outperform” rating and a $17.00 target price on the stock.
In other news, major shareholder Bio-Exagen L.P. H.I.G. purchased 425,000 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were acquired at an average cost of $14.00 per share, with a total value of $5,950,000.00.
A number of hedge funds have recently bought and sold shares of the stock. Dean Capital Investments Management LLC acquired a new position in Exagen during the 3rd quarter worth approximately $221,000. Russell Investments Group Ltd. acquired a new position in Exagen during the 3rd quarter worth approximately $967,000. Teacher Retirement System of Texas acquired a new position in Exagen during the 3rd quarter worth approximately $310,000. Finally, Perkins Capital Management Inc. acquired a new position in Exagen during the 3rd quarter worth approximately $1,355,000.
Shares of Exagen stock traded down $0.10 on Monday, hitting $19.31. 38,729 shares of the company’s stock traded hands, compared to its average volume of 62,400. Exagen has a one year low of $11.54 and a one year high of $21.05. The firm’s fifty day moving average price is $14.82.
Exagen Company Profile
Exagen Inc operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia.
Recommended Story: Why Net Income is Important to Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.